Proteomics International Laboratories has signed a licence agreement to sell its PromarkerD predictive test for diabetic kidney disease (DKD) in Chile, expanding its reach into the lucrative Central and South American markets.
The deal with long-standing partner Omics Global Solutions will see the test made available in the Republic of Chile, which management says is home to 1.7 million adults living with diabetes – the equivalent of one in eight adults.
Article: Chile deal opens wider American markets for Proteomics